

FOI REF: 23/181

14th April 2023

Tel: 0300 131 4500
Website: www.esht.nhs.uk

FREEDOM OF INFORMATION ACT

I am responding to your request for information under the Freedom of Information Act. The answers to your specific questions are as follows:

Q1. How many urothelial cancer patients have been treated in the past 3 months with the following agents:

• Avelumab	9
• Atezolizumab	0
• Carboplatin with Gemcitabine	0
• Carboplatin single or in any other combination	0
• Cisplatin with Gemcitabine	0
• Cisplatin single or in any other combination	0
• Nivolumab	10
• Pembrolizumab	5
• Any other regimen including Paclitaxel	0
• Any other chemotherapy regimen	14
• Other active systemic anti-cancer therapy	0
• Palliative care only	0

Section 12(1) applied,
please see below.

East Sussex Healthcare NHS Trust does not centrally record patients being treated for palliative care only. To enable the Trust to provide this information would require a manual review of patients' notes to establish if we hold this information, and discussing each patient with individual clinicians, which we estimate would take in excess of 18 hours. We are therefore applying Section 12(1) to this part of your request.

Cont.../

Section 12(1) of the Act allows a public authority to refuse to comply with a request for information if the authority estimates that the cost of compliance would exceed the 'appropriate limit', as defined by the Freedom of Information and Data Protection (Appropriate Limit and Fees) Regulations 2004 (the Regulations). These state that this cost limit is £450 for public authorities which are not part of central government or the armed forces. The costs are calculated at £25 per hour per person regardless of the rate of pay, which means that the limit will be exceeded if the work involved would exceed 18 hours. The Trust estimates that the cost of complying with this request would significantly exceed the above limit.

Q2. How many colorectal cancer [CRC] patients have been treated in the past 3 months with the following agents:

• Aflibercept	0
• Bevacizumab	0
• Capecitabine	1
• CAPIRI	4
• CAPOX (XELOX)	11
• Cetuximab in combination with FOLFIRI	5
• Cetuximab in combination with FOLFOX	0
• Cetuximab not in combination with FOLFIRI or FOLFOX	6
• Irinotecan only	0
• FOLFIRI	7
• FOLFOX	10
• Fluorouracil (5FU) only	0
• Oxaliplatin only	0
• Panitumumab in combination with FOLFIRI	0
• Panitumumab in combination with FOLFOX	0
• Panitumumab not in combination with FOLFIRI or FOLFOX	0
• Pembrolizumab	0
• Nivolumab	0
• Raltitrexed	0
• Ramucirumab	0
• Regorafenib	0
• Sorafenib	0
• Other active systemic anti-cancer therapy	9
• Palliative care only	

Section 12(1) applied,
please see question 1.

If I can be of any further assistance, please do not hesitate to contact me.

Should you be dissatisfied with the Trust's response to your request, you have the right to request an internal review. Please write to the Freedom of Information Department (esh-tr.foi@nhs.net), quoting the above reference, within 40 working days. The Trust is not obliged to accept an internal review after this date.

Should you still be dissatisfied with your FOI request, you have the right of complaint to the Information Commissioner at the following address:

The Information Commissioner's Office
Wycliffe House
Water Lane
Wilmslow
Cheshire SK9 5AF

Telephone: 0303 123 1113

Yours faithfully

Linda Thornhill (Mrs)
Corporate Governance Manager
esh-tr.foi@nhs.net